Letter from the Editor

Home > Neurology > AAN 2019

Read the full Report (pdf)

American Academy of Neurology

4–10 May 2019, Philadelphia, USA

Featured articles

Letter from the Editor

Editor

Prof. Hans-Peter Hartung, Heinrich-Heine-University, Düsseldorf, Germany

Conference

AAN 2019

30 July, 2019 23:52

Interview with Prof. Natalia Rost

Expert

Prof. Natalia Rost, Massachusetts General Hospital / Harvard Medical School, USA

Conference

AAN 2019

30 July, 2019 09:10

Online First

Alzheimer's Disease and other Dementias

Amyloid PET in cognitively impaired patients

Presented By

Prof. Gil Rabinovici, University of California San Francisco, USA

Trial

IDEAS

Conference

AAN 2019

30 July, 2019 23:14

Tight blood pressure control lowers risk of mild cognitive impairment

Presented By

Dr Jeff Williamson, Wake Forest Baptist Medical Center, Winston-Salem, USA

Trial

SPRINT MIND

Conference

AAN 2019

30 July, 2019 22:16

Two experimental antibodies reduce amyloid levels

Trial

Phase 3, PRIME, ENGAGE, EMERGE

Conference

AAN 2019

30 July, 2019 21:20

How to implement brain-healthy behaviour in clinical practice

Conference

AAN 2019

30 July, 2019 09:21

Epilepsy

Cannabidiol effective in children with Dravet syndrome

Trial

GWPCARE

Conference

AAN 2019

30 July, 2019 23:23

Possible role of brivaracetam in controlling acute seizures

Conference

AAN 2019

30 July, 2019 22:24

Long term safety of diazepam nasal spray

Conference

AAN 2019

30 July, 2019 20:25

Brain-responsive neurostimulation reduces seizures

Conference

AAN 2019

30 July, 2019 09:30

Headache and Migraine

Atogepant effective and safe for migraine prevention

Conference

AAN 2019

30 July, 2019 23:33

Long-term efficacy and safety of erenumab

Trial

Phase 3, STRIVE

Conference

AAN 2019

30 July, 2019 22:34

Eptinezumab reduces mean monthly migraine days

Trial

Phase 3, PROMISE

Conference

AAN 2019

30 July, 2019 21:35

Fremanezumab efficacy and safety maintained over 1 year

Conference

AAN 2019

30 July, 2019 20:36

Lasmiditan: rapid onset of efficacy in acute migraine

Trial

Phase 3, SPARTAN, SAMURAI

Conference

AAN 2019

30 July, 2019 19:37

New formulation of rimegepant: fast onset of action

Conference

AAN 2019

30 July, 2019 18:38

Efficacy, tolerability, and safety of ubrogepant confirmed

Trial

Phase 3, ACHIEVE

Conference

AAN 2019

30 July, 2019 17:39

Galcanezumab reduces cluster headache frequency

Expert

Dr David Dodick, Mayo Clinic, Phoenix, USA

Conference

AAN 2019

30 July, 2019 16:40

Non-invasive vagus nerve stimulation for cluster headache

Conference

AAN 2019

30 July, 2019 09:41

Multiple Sclerosis and NMOSD

Three very promising new treatments of NMOSD

Presented By

Dr Stacey Clardy & Prof. Bruce Cree

Trial

PREVENT, SAkuraSky

Conference

AAN 2019

30 July, 2019 23:07

Immune tolerance by peptide-loaded tolerogenic dendritic cells

Expert

Dr Irati Zubizarreta, Institut d’Investigacions Biomediques August Pi Sunyer, Spain

Conference

AAN 2019

30 July, 2019 22:08

New compounds for MS treatment

Trial

Phase 2, RADIUS-R, RADIUS-D

Conference

AAN 2019

30 July, 2019 21:10

Sequencing of high-efficacy disease-modifying treatments in MS

Trial

OCTAVE

Conference

AAN 2019

30 July, 2019 20:12

Biotin, ocrelizumab, and ibudilast in progressive MS

Expert

Dr Andrew Goodman, University of Rochester School of Medicine and Dentistry, USA

Trial

ORATORIO, Phase 3; SPRINT-MS, Phase 2; MS-SPI, Phase 3

Conference

AAN 2019

30 July, 2019 19:15

No increased MS relapse risk postpartum

Expert

Dr Annette Langer-Gould, Kaiser Permanente Southern California, Pasadena, USA

Conference

AAN 2019

30 July, 2019 18:16

McDonald Criteria MS often misapplied and misunderstood

Conference

AAN 2019

30 July, 2019 17:17

Clinical relevance of neurofilament light chain levels

Trial

Phase 3, EXPAND, ADVANCE, CHAMPS, MSCRG, SENTINEL

Conference

AAN 2019

30 July, 2019 10:19

Neuromuscular Disorders

Encouraging results zilucoplan in myasthenia gravis

Presented By

Prof. James Howard & Dr Josep Gamez

Conference

AAN 2019

30 July, 2019 23:23

Experimental drug shows promise for SOD1-ALS

Presented By

Prof. Timothy Miller & Prof. Jinsy Andrews

Conference

AAN 2019

30 July, 2019 22:25

First-ever effective and safe treatment of CMT1A

Presented By

Dr Florian Thomas, Hackensack University Medical Center, New York, USA

Trial

Phase 3, PLEO-CMT

Conference

AAN 2019

30 July, 2019 21:26

Updates on three treatments of spinal muscular atrophy

Trial

ENDEAR, SHINE, FIREFISH, STR1VE

Conference

AAN 2019

30 July, 2019 10:28

Parkinson’s Disease and other Movement Disorders

Leukaemia and hypertension therapies tested in Parkinson’s disease

Presented By

Dr Charbel Moussa & Dr Tanya Simuni

Conference

AAN 2019

30 July, 2019 23:29

Levodopa oral inhalation powder

Trial

SPAN-PD

Conference

AAN 2019

30 July, 2019 22:30

Mesenchymal stem cells in a proof-of-concept study

Conference

AAN 2019

30 July, 2019 21:31

T-type-calcium channel modulator in essential tremor

Conference

AAN 2019

30 July, 2019 20:32

Experimental Parkinson’s disease therapies

Trial

BIPARK-1, BIPARK-2, MOVES-PD

Conference

AAN 2019

30 July, 2019 19:34

Laquinimod does not improve motor scores in Huntington disease

Trial

Phase 3, LEGATO-HD

Conference

AAN 2019

30 July, 2019 10:36

Stroke

Lack of consensus on anticoagulation after acute ischemic stroke in atrial fibrillation

Conference

AAN 2019

30 July, 2019 23:38

Direct oral anticoagulants compared to vitamin K antagonist in atrial fibrillation -related cerebral ischemia

Trial

ARISTOPHANES

Conference

AAN 2019

30 July, 2019 22:39

Depressive symptoms associated with increased stroke risk

Conference

AAN 2019

30 July, 2019 10:40

Miscellaneous

Possibly lifesaving therapy in refractory PML

Presented By

Dr Erin Beck, National Institute of Health in Bethesda, USA

Conference

AAN 2019

30 July, 2019 23:42

New AAN guideline for treating Tourette syndrome

Expert

Dr Tamara Pringsheim, University of Calgary, Canada

Conference

AAN 2019

30 July, 2019 22:43

Subspecialty teleneurology: feasible and highly valued

Expert

Dr Lindsey Ross, Cleveland Clinic, Ohio, USA

Conference

AAN 2019

30 July, 2019 21:44

OV101 (gaboxadol) as therapy of Angelman syndrome

Trial

Phase 2, STARS

Conference

AAN 2019

30 July, 2019 10:45

Featured articles

CONTENTS

Online First

Alzheimer's Disease and other Dementias

Epilepsy

Headache and Migraine

Multiple Sclerosis and NMOSD

Neuromuscular Disorders

Parkinson’s Disease and other Movement Disorders

Stroke

Miscellaneous